Dr. Peng Du 杜鹏
Chief Physician, Associate Professor
Department of Urology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and minimally invasive surgery for urologic and male reproductive system tumors, including kidney, bladder, prostate, and testicular cancers.
Dr. Du holds an MD and serves as Deputy Director of Urologic Tumor Surgery at Peking University Cancer Hospital. Dr. Du conducted research at Cardiff University (2010–2011) and trained in robotic minimally invasive surgery at the University of Rochester Medical Center (2013). Dr. Du has published over 10 papers, including 8 SCI articles, and contributes to national urology guidelines and textbooks.
Professional roles
- Chair, Early Cancer Screening Professional Committee, Beijing Anti-Cancer Association
- Member, Robot Group of Urology Branch, Beijing Medical Association
- Member, Urothelial Carcinoma Committee, Chinese Society of Clinical Oncology (CSCO)
- Editorial Board Member, Journal of Clinical Urology
Name order: in Chinese the family name comes first (Du Peng). Papers usually list the name as Peng Du or Du P.
Selected publications
56 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Mol Sci, 2026 (senior author): Cancer Cachexia in Advanced Renal Cell Carcinoma: From Molecular Mechanisms to Prognostic Assessment. PubMed 42737841
- Beijing Da Xue Xue Bao Yi Xue Ban, 2026 (senior author): [Feasibility and clinical value of a prostate cancer screening model based on biparametric magnetic resonance imaging combined with prostate-specific antigen in a Chinese population]. PubMed 42493445
- J Clin Med, 2026 (senior author): The Diagnostic and Prognostic Value of Immunohistochemical Markers in Bladder Cancer: A Real-World Study of 477 Patients. PubMed 42590225
- Transl Androl Urol, 2026 (senior author): Prognostic and immunological implications of a mitophagy-associated gene signature in bladder cancer. PubMed 42436798
- Int J Mol Sci, 2026 (senior author): HCN2 Promotes BGN Transcription via REST to Regulate Ferroptosis and Tumor Progression in Bladder Cancer. PubMed 42074076
- Transl Cancer Res, 2026 (senior author): Neoadjuvant androgen deprivation therapy with bicalutamide compared to hormonal agents in treating high-risk prostate cancer: a real-world cohort study. PubMed 41815147
- Transl Androl Urol, 2026 (senior author): Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer. PubMed 41809777
- Transl Androl Urol, 2025 (senior author): Comparing the long-term prognosis and renal function changes of partial nephrectomy (PN) and radical nephrectomy (RN) in T1 stage renal cell carcinoma patients. PubMed 40226071
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion